FE
Feener Edward P.
Chief Scientific Officer
OFFICERM
Insider track record
ExecutiveNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Feener Edward P., Chief Scientific Officer. Officer active across 1 company, notably KalVista Pharmaceuticals, Inc.. Aggregated, 18 reports have been published. Breakdown: 0 buy · 7 sells. Total volume traded: €1.8m. History available since 3 May 2021. The latest transaction was filed on 14 February 2024 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Feener Edward P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
18,789 sharesCommon StockSEC:0001415889-24-014007:0
18,788 sharesCommon StockSEC:0001415889-24-004718:0
28,171 shares@ US$15.009312.7% of flowCommon StockSEC:0001415889-24-004118:0
60,000 sharesCommon StockSEC:0001415889-24-003483:0
22,679 shares@ US$13.03038.6% of flowCommon StockSEC:0001209191-24-001515:0
17,221 shares@ US$13.00746.6% of flowCommon StockSEC:0001209191-24-001391:0
11,497 sharesCommon StockSEC:0001209191-23-056276:0
11,494 sharesCommon StockSEC:0001209191-23-046823:0
4,205 sharesCommon StockSEC:0001209191-23-031293:0
4,204 sharesCommon StockSEC:0001209191-23-012318:0
1,774 sharesCommon StockSEC:0001209191-22-058128:0
1,773 sharesCommon StockSEC:0001209191-22-046882:0
33,800 shares@ US$7.070.015% mcap9.4% of flowCommon StockSEC:0001209191-22-002887:0
6,000 shares@ US$18.07060.0066% mcap4.2% of flowCommon StockSEC:0001209191-21-062736:0
6,000 shares@ US$20.52235.1% of flowCommon StockSEC:0001209191-21-049799:0
25,786 shares@ US$26.808528.0% of flowCommon StockSEC:0001209191-21-037887:0
6,000 shares@ US$24.84186.1% of flowCommon StockSEC:0001209191-21-031013:0
6,000 shares@ US$10.212.5% of flowCommon StockSEC:0001209191-21-030753:0
About Feener Edward P.
Edward P. Feener is the Chief Scientific Officer at KalVista Pharmaceuticals, Inc. In this role, he is responsible for leading the company's research and development initiatives. His scientific expertise is essential for innovation and the development of new treatments.